On December 17, 2021 Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, reported the presentation of new preclinical data on the company’s anti-CD27 agonist monoclonal antibody program at the virtual European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Immuno-Oncology Congress 2021, that took place December 8-11, 2021 (Press release, Kineta, DEC 17, 2021, View Source;utm_medium=rss&utm_campaign=kineta-presented-new-preclinical-data-on-its-anti-cd27-agonist-antibody-program-at-the-esmo-immuno-oncology-congress-2021 [SID1234597371]). Thierry Guillaudeux, PhD, Senior Vice President Immuno-oncology at Kineta, presented a poster revealing compelling in vitro data on the T cell activation and cytokine induction of Kineta’s lead anti-CD27 agonist antibodies. Additionally, Dr. Guillaudeux presented new in vivo data demonstrating strong anti-tumor efficacy as a monotherapy in an MB49 tumor model.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are excited to see the robust preclinical data of our anti-CD27 agonist antibodies that was presented at ESMO (Free ESMO Whitepaper)" said Thierry Guillaudeux, PhD, Senior Vice President Immuno-oncology at Kineta. "These data demonstrate the potential of our future lead anti-CD27 agonist antibodies as a monotherapy. Additionally, we believe there are combinations with other immunotherapies that can provide strong synergistic efficacy and improve outcomes for patients with cancer."
Key results from the ESMO (Free ESMO Whitepaper) poster presentation:
Evaluated 15 leads out of 147 fully human anti-CD27 monoclonal antibodies with unique sequences
Human T cell activation assay showed strong increased in proliferation and cytokine secretion for 3 mAbs
Surrogate in vivo model with anti-mouse CD27 agonist showed significant anti-tumor response
huCD27 transgenic mice will serve as our model for further in vivo studies to select our lead anti-CD27 agonist antibody
Presentation Details:
Title: Novel fully human agonist antibodies against the T-cell costimulatory receptor CD27 shape adaptive anti-tumor immunity
Date Presented: December 8-11, 2021
Presenter: Thierry Guillaudeux, PhD
Poster: Click on the link below to view the poster:
CD27 Publications – Poster Presentation at ESMO (Free ESMO Whitepaper) 2021
Anti-CD27 mAb program: Kineta has developed a diverse set of anti-CD27 agonist antibodies. They are fully human monoclonal antibodies (mAbs) that demonstrate low nanomolar (nM) binding affinity to CD27 in humans. In preclinical studies, Kineta’s selected lead anti-CD27 agonist mAbs induce T cell proliferation and secretion of cytokines involved in T cell priming and recruitment, demonstrating the ability to potentiate new anti-tumor responses. Kineta is in the final stage of lead selection and plans to nominate a clinical candidate in Q1-Q2 2022.